ÂÜÀòÂÒÂ×

Paul Pang is an accomplished biomedical researcher with extensive experience in drug discovery and disease modeling. Currently serving as Associate Director at Greenstone Biosciences since February 2022, Paul Pang leads team projects from concept to FDA approval, specializing in patient-derived human iPSCs and novel therapeutics. Prior to this role, Paul Pang held positions at Stanford University as a Senior Scientist and Postdoctoral Fellow, focusing on human iPSCs for drug discovery and disease modeling. Paul Pang's academic journey includes a Ph.D. from Baylor College of Medicine, with a focus on myotonic dystrophy, as well as advanced degrees in bioengineering from Harvard University and medical sciences from Boston University, complemented by a Bachelor's in Microbiology from the University of Maryland.